Castle Biosciences, Inc. (CSTL)

29.77 +0.25 (+0.85%) As of 02:33PM EDT. Market open.

Castle Biosciences, Inc.

505 South Friendswood Drive
Suite 401
Friendswood, TX 77546
United States
866 788 9007
https://castlebiosciences.com

Sector(s): Healthcare
Industry: Diagnostics & Research
Full-time employees: 703

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Derek J. Maetzold	Founder, CEO, President & Director	1.61M	N/A	1962
Mr. Frank Stokes	CFO & Treasurer	880.25k	75.52k	1970
Ms. Kristen M. Oelschlager R.N.	Chief Operating Officer	828.48k	234.2k	1968
Mr. Tobin W. Juvenal	Chief Commercial Officer	829.1k	126.36k	1960
Camilla Zuckero	Vice President of Investor Relations & Corporate Affairs	N/A	N/A	N/A
Ms. Alice Bahner Izzo	Senior Vice President of Marketing	N/A	N/A	N/A
Mr. Kevin Doman	Vice President of Sales	N/A	N/A	N/A
Ms. Keli Greenberg	VP of Human Resources & Executive Director of Human Resources	N/A	N/A	N/A
Dr. Robert W. Cook Ph.D.	Senior Vice President of Research & Development	N/A	N/A	1972
Dr. Matthew Goldberg M.D.	Senior Vice President of Medical	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

Corporate governance

Castle Biosciences, Inc.’s ISS governance QualityScore as of 1 October 2024 is 7. The pillar scores are Audit: 4; Board: 6; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.